TARGET AUDIENCE:
Medical oncologists and other allied healthcare professionals.

GLOBAL LEARNING OBJECTIVES:
Upon completion of this activity, participants should be able to:

• Critically evaluate data from the pivotal clinical trials integrating novel molecular therapeutics into the treatment of various solid tumors, and communicate the scientific and patient-level advantages of selective cellular targeting.
• Describe the unique research and development challenges associated with identification of effective dosing, scheduling and duration of biologic and small-molecule anti-tumor agents, and explain how investigators have modified clinical trial endpoints to address these issues.
• Evaluate the safety and tolerability of novel targeted compounds, and identify evidence-based strategies to manage side effects.
• Review the historical and evolving role of combination treatment strategies in the management of cancer, exploring the biologic rationale for concomitant versus sequential integration of cytotoxic-novel and novel-novel dual tumor targeting.
• Identify several distinct molecular pathways that support the growth, development, survival or invasive action of neoplastic cells, and describe the investigational agents that have demonstrated early anti-cancer activity through these mechanisms.
• Discuss the integral role of clinical trial participation in maximizing cancer treatment advances, and counsel appropriately selected patients on the relevance and availability of ongoing research studies.

CME EVALUATION:
An evaluation form will be given to each participant at the conclusion of this activity.

ACCREDITATION STATEMENT:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT:
Research To Practice designates this educational activity for a maximum of 2.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

DISCLOSURE POLICY:
As a provider accredited by the Accreditation Council for Continuing Medical Education, it is the policy of Research To Practice to require the disclosure of any significant financial interest or any other relationship the sponsor or faculty members have with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. Financial disclosures and disclosures of discussions of unlabeled/ unapproved uses of drugs or devices will be provided in meeting course materials.